"Breakthrough Achievement: Indian-Manufactured CAR-T Cell Therapy Successfully Renders Patient Cancer-Free"

In a significant stride, India's CAR-T cell therapy, an indigenous cancer treatment, recently garnered approval from the Central Drugs Standard Control Organization (CDSCO) for commercial use. This revolutionary therapy involves the genetic reprogramming of a patient's immune system to combat cancer. Dr. (Col) VK Gupta, a distinguished gastroenterologist based in Delhi, stands as the inaugural patient declared "cancer-free" through this breakthrough treatment, which he acquired at a fraction of the cost compared to international alternatives.

CAR-T cell therapy entails the manipulation of a patient's T cells, a subset of white blood cells vital for immune response, in a laboratory setting. These modified T cells are engineered to express a chimeric antigen receptor (CAR) protein, enabling them to identify and eliminate cancer cells upon reinfusion into the patient's body.

NexCAR19, the pioneering CAR-T cell therapy developed by ImmunoACT, a venture incubated at the esteemed Indian Institute of Technology Bombay (IITB) in collaboration with Tata Memorial Hospital, targets B-cell cancers such as leukemia and lymphoma. With the recent approval, NexCAR19 is now accessible across over 30 hospitals spanning more than 10 cities in India, offering hope to eligible patients aged 15 and above grappling with B-cell malignancies.